Modality
Multispecific
MOA
SGLT2i
Target
CD20
Pathway
Notch
CML
Development Pipeline
Preclinical
Aug 2021
→ Sep 2028
PreclinicalCurrent
NCT08503760
2,631 pts·CML
2021-08→2028-09·Completed
2,631 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-09-232.5y awayInterim· CML
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Complet…
Catalysts
Interim
2028-09-23 · 2.5y away
CML
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08503760 | Preclinical | CML | Completed | 2631 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 |